| Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers I Landa, T Ibrahimpasic, L Boucai, R Sinha, JA Knauf, RH Shah, S Dogan, ... The Journal of clinical investigation 126 (3), 1052-1066, 2016 | 1187 | 2016 |
| Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine J Nagarajah, M Le, JA Knauf, G Ferrandino, C Montero-Conde, ... The Journal of clinical investigation 126 (11), 4119-4124, 2016 | 136 | 2016 |
| Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer E Avilla, V Guarino, C Visciano, F Liotti, M Svelto, GP Krishnamoorthy, ... Cancer research 71 (5), 1792-1804, 2011 | 121 | 2011 |
| SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies M Saqcena, LJ Leandro-Garcia, JLV Maag, V Tchekmedyian, ... Cancer Discovery 11 (5), 1158-1175, 2021 | 80 | 2021 |
| EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC GP Krishnamoorthy, NR Davidson, SD Leach, Z Zhao, SW Lowe, G Lee, ... Cancer discovery 9 (2), 264-281, 2019 | 79 | 2019 |
| Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers BR Untch, V Dos Anjos, MER Garcia-Rendueles, JA Knauf, ... Cancer research 78 (16), 4642-4657, 2018 | 77 | 2018 |
| Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation GP Krishnamoorthy, T Guida, L Alfano, E Avilla, M Santoro, F Carlomagno, ... Journal of Biological Chemistry 288 (24), 17481-17494, 2013 | 66 | 2013 |
| Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia E Wang, JMB Pineda, WJ Kim, S Chen, J Bourcier, M Stahl, SJ Hogg, ... Cancer Cell 41 (1), 164-180. e8, 2023 | 50 | 2023 |
| Pathogenesis of cancers derived from thyroid follicular cells JA Fagin, GP Krishnamoorthy, I Landa Nature reviews Cancer 23 (9), 631-650, 2023 | 30 | 2023 |
| Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy L Boucai, M Saqcena, F Kuo, RK Grewal, N Socci, JA Knauf, ... Clinical Cancer Research 29 (8), 1620-1630, 2023 | 25 | 2023 |
| Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors MER Garcia-Rendueles, G Krishnamoorthy, M Saqcena, A Acuña-Ruiz, ... Molecular Cancer 21 (1), 213, 2022 | 23 | 2022 |
| Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase L Boucai, F Salas-Lucia, GP Krishnamoorthy, E Sherman, CM Rudin, ... JCO Precision Oncology 6, e2100496, 2022 | 15 | 2022 |
| Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers KA Luckett, JR Cracchiolo, GP Krishnamoorthy, LJ Leandro-Garcia, ... Endocrine-Related Cancer 28 (6), 391-402, 2021 | 15 | 2021 |
| Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric Effects I Landa, CEM Thornton, B Xu, J Haase, GP Krishnamoorthy, J Hao, ... Molecular Cancer Research 21 (11), 1163-1175, 2023 | 8 | 2023 |
| RBM10 loss in thyroid cancer leads to aberrant splicing of cytoskeletal and extracellular matrix mRNAs and increased metastatic fitness GP Krishnamoorthy, A Glover, B Untch, M Saqcena, D Vukel, K Berman, ... Cancer Research 82 (12_Supplement), 986-986, 2022 | 3 | 2022 |
| Targetable treatment resistance in thyroid cancer with clonal hematopoiesis V Tiedje, PS Vela, JL Yang, BR Untch, L Boucai, AJ Stonestrom, AB Costa, ... bioRxiv, 2024.10. 10.617685, 2024 | 1 | 2024 |
| RBM10 loss induces aberrant splicing of cytoskeletal and extracellular matrix mRNAs and promotes metastatic fitness GP Krishnamoorthy, AR Glover, BR Untch, N Sigcha-Coello, B Xu, ... bioRxiv, 2024 | 1 | 2024 |
| Telomerase reactivation induces progression of mouse BrafV600E-driven thyroid cancers without telomere lengthening I Landa, CEM Thornton, B Xu, J Haase, GP Krishnamoorthy, J Hao, ... bioRxiv, 2023 | 1 | 2023 |
| Functional characterization of EIF1AX mutations in thyroid cancer predicts for gain of function by increasing translational rate with concomitant derepression of upstream … GP Krishnamoorthy, I Landa, JA Knauf, J Nagarajah, G Rätsch, ... Cancer Research 76 (14_Supplement), 892-892, 2016 | 1 | 2016 |
| RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs GP Krishnamoorthy, AR Glover, BR Untch, N Sigcha-Coello, B Xu, ... Journal of Experimental Medicine 222 (5), 2025 | | 2025 |